IP Library › Patent Application 17722051
Patent Application
App. No. 17/722,051

NON-CODING RNA FOR DETECTION OF CANCER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/722,051
Abstract

The present disclosure relates generally to detection on non-coding RNAS molecules in a sample or diagnosis of subject based upon detection or quantification of non-coding nucleic acid sequences in a sample, specifically to identify and use of molecular biomarkers for cancer including breast cancer.

Claims (23)

1 . A method for sequencing a ribonucleic acid (RNA) molecule from a cell-free sample, comprising:

(a) providing said cell-free sample comprising said RNA molecule, wherein said RNA molecule comprises a non-coding sequence;

(b) subjecting said RNA molecule to reverse transcription to generate a complementary deoxyribonucleic acid (cDNA) molecule, wherein said cDNA molecule comprises a sequence corresponding to said non-coding sequence of said RNA molecule; and

(c) subjecting said cDNA molecule or derivative thereof to sequencing-by-synthesis to identify said non-coding sequence.

2 . The method of claim 1 , wherein said RNA molecule is an orphan non-coding RNA (oncRNA).

3 . The method of claim 1 , wherein said RNA molecule comprises T3p or functional fragment thereof.

4 . The method of claim 1 , further comprising, after (a), isolating said RNA molecule from other components of said cell-free sample.

5 . The method of claim 4 , wherein said isolating comprises filtration.

6 . The method of claim 1 , further comprising using a result of said sequencing-by-synthesis to determine an amount of said non-coding sequence in said cell-free sample.

7 . The method of claim 1 , wherein said cell-free sample comprises serum.

8 . The method of claim 1 , wherein said cell-free sample comprises whole blood.

9 . The method of claim 1 , wherein said cell-free sample comprises plasma.

10 . The method of claim 1 , wherein said cell-free sample comprises urine.

11 . The method of claim 1 , wherein said cell-free sample comprises lymph.

12 . The method of claim 1 , wherein said cell-free sample comprises saliva.

13 . The method of claim 1 , wherein the volume of cell-free sample is about 20 microliters to about 2 milliliters.

14 . The method of claim 11 , wherein the volume of cell-free sample is about 100 microliters to about 500 microliters.

15 . The method of claim 1 , wherein said sequencing-by-synthesis generates sequencing reads, which sequencing reads are processed to identify said non-coding sequence.

16 . The method of claim 1 , wherein said RNA molecule has a length of less than 200 nucleotides.

17 . The method of claim 13 , wherein said RNA molecule has a length between 50 and 100 nucleotides.

18 . The method of claim 1 , wherein said non-coding sequence is indicative of cancer.

19 . The method of claim 1 , wherein said cancer is breast cancer.

20 . The method claim 1 , further comprising, after (b), amplifying said cDNA molecule.